Search for dissertations about: "Gustav Ullenhag"
Showing result 1 - 5 of 6 swedish dissertations containing the words Gustav Ullenhag.
-
1. Vaccine Therapy of Colorectal Cancer Patients with Tumor Associated Antigens
Abstract : In this thesis, two different vaccines were evaluated as adjuvant therapy for patients with colorectal cancer. The ability of the two candidate vaccines to generate antigen-specific cellular and humoral responses, respectively, was studied. READ MORE
-
2. Antibody-based Cancer Immunotherapy : Personalization, response prediction and safety considerations
Abstract : Antibody-based therapeutics have remarkably improved the field of immuno-oncology. Multiple monoclonal antibodies (mAbs) are approved for clinical use, and numerous antibodies are under clinical development. The scope of this thesis is to study the personalization of antibody-based immunotherapeutics and tools to predict their efficacy and safety. READ MORE
-
3. Intratumoral CD40 stimulating therapy in patients with advanced cancer
Abstract : CD40-CD40L interaction activates DCs to become highly efficient APCs and skews the adaptive immune response towards a Th I phenotype driving cytotoxic T cells, M1 macrophages and natural killer cells. Furthermore, engagement of CD40L to CD40 positive cancer cells can have direct anti-proliferative effects, induce apoptosis and increase expression of MHC and other co-stimulatory molecules, thereby enhancing cancer cell recognition. READ MORE
-
4. The role of imaging in follow-up and prognosis of patients radically operated for melanoma
Abstract : Cutaneous malignant melanoma (CMM) is the cancer type in Sweden with the most rapidly increasing incidence. This thesis investigated if whole-body imaging improves the follow-up scheme post-surgery in high-risk CMM patients and explored the long-term outcomes for early-stage melanoma patients compared to the general population. READ MORE
-
5. Intratumoral Predictive Markers in Metastatic Renal Cancer Patients
Abstract : There is no established predictive marker for the treatment of metastatic renal cell cancer (mRCC) patients. With a predictive marker, patients unlikely to respond could be selected upfront and offered other therapy options. Thereby, unnecessary toxicity could be avoided and costs would be reduced. READ MORE